Format

Send to

Choose Destination
Onco Targets Ther. 2017 Apr 6;10:2003-2007. doi: 10.2147/OTT.S127498. eCollection 2017.

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.

Author information

1
Department of Chemoradiotherapy, Yinzhou Hospital Affiliated to Ningbo University School of Medicine, Ningbo, People's Republic of China.

Abstract

PURPOSE:

Programmed death-ligand 1 (PD-L1) is found to be overexpressed in non-small cell lung cancer. The present study intended to evaluate the status of PD-L1 expression in patients with resection and recurrent lung adenocarcinoma.

PATIENTS AND METHODS:

Matched resection and recurrent tumor samples were harvested from 65 lung adenocarcinoma patients. Immunohistochemistry was used to evaluate the status of PD-L1 expression. Kaplan-Meier method was used for survival analysis.

RESULTS:

A total of 65 patients of lung adenocarcinoma were enrolled. They underwent complete resection and had recurrence after adjuvant treatment. PD-L1 expression was identified in 43.1% (28/65) of resection samples vs 55.4% (36/65) of recurrent samples. Ten patients shifted from negative to positive, whereas another two samples showed the opposite. Patients with PD-L1 expression showed worse disease-free survival than the PD-L1-negative counterparts. The expression of PD-L1 in recurrent samples was a significant favorable factor for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (11.2 vs 8.2 months, P=0.030).

CONCLUSION:

The status of PD-L1 expression may alter between resection and recurrent samples. Also, the status of PD-L1 expression after recurrence is a better prognostic factor for EGFR-TKIs.

KEYWORDS:

lung adenocarcinoma; overexpression; programmed death-ligand 1; survival

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center